Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Ras and Rab interactor 1 (RIN1) is an effector of H-Ras, which plays an important role in the development and progression of carcinomas, but it has not been reported in bladder cancer. Hence, the association of RIN1 expression with prognosis of bladder urothelial carcinoma (UC) was examined. RIN1 mRNA and protein expression in 20 paired UCs and the adjacent normal tissues was detected by quantitative reverse transcription polymerase chain reaction and Western blot. The expression of RIN1 protein in 96 specimens of UCs and 22 specimens of adjacent normal bladder tissues were analyzed by immunohistochemistry. The overall survival (OS) was assessed by univariate and multivariate analysis. Moreover, the progression-free survival (PFS) and recurrence-free survival (RFS), classified by the clinicopathologic features with RIN1 expression, were assessed by multivariate analysis. RIN1 mRNA and protein level was higher in UCs than in the adjacent normal tissues (P < 0.01). Enhanced RIN1 immunoexpression was associated with high histologic grades (P = 0.046), cancer progression (P = 0.047) as well as Ki-67 expression (P = 0.023). Furthermore, the 5-year survival rate was 29% in the subgroup with high level of RIN1 expression, while it was 43% in the subgroup with normal level of RIN1 expression (P < 0.05). Importantly, RIN1 level was revealed as the significant independent prognostic factor for death (P = 0.023) and progression (P = 0.003), but a weak contribution for recurrence (P = 0.063). Collectively, RIN1 expression could be a potential prognostic predictor for UC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.

    Article  PubMed  Google Scholar 

  3. Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ O, Egorin MJ. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol. 2003;21:697–703.

    Article  PubMed  CAS  Google Scholar 

  4. Colicelli J, Nicolette C, Birchmeier C, Rodgers L, Riggs M, Wigler M. Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1991;88:2913–7.

    Article  PubMed  CAS  Google Scholar 

  5. Han L, Colicelli J. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1. Mol Cell Biol. 1995;15:1318–23.

    PubMed  CAS  Google Scholar 

  6. Bliss JM, Venkatesh B, Colicelli J. The RIN family of Ras effectors. Methods Enzymol. 2006;407:335–44.

    Article  PubMed  CAS  Google Scholar 

  7. Han L, Wong D, Dhaka A, Afar D, White M, Xie W, Herschman H, Witte O, Colicelli J. Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc Natl Acad Sci USA. 1997;94:4954–9.

    Article  PubMed  CAS  Google Scholar 

  8. Hu H, Bliss JM, Wang Y, Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol. 2005;15:815–23.

    Article  PubMed  CAS  Google Scholar 

  9. Cao X, Tanis KQ, Koleske AJ, Colicelli J. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms. J Biol Chem. 2008;283:31401–7.

    Article  PubMed  CAS  Google Scholar 

  10. Ziegler S, Eiseler T, Scholz RP, Beck A, Link G, Hausser A. A novel protein kinase D phosphorylation site in the tumour suppressor Rab interactor 1 is critical for coordination of cell migration. Mol Biol Cell. 2011;22:570–80.

    Article  PubMed  CAS  Google Scholar 

  11. Hunker CM, Giambini H, Galvis A, Hall J, Kruk I, Veisaga ML, Barbieri MA. Rin1 regulates insulin receptor signal transduction pathways. Exp Cell Res. 2006;312:1106–18.

    Article  PubMed  CAS  Google Scholar 

  12. Hunker CM, Galvis A, Veisaga ML, Barbieri MA. Rin1 is a negative regulator of the IL3 receptor signal transduction pathways. Anticancer Res. 2006;26:905–16.

    PubMed  CAS  Google Scholar 

  13. Barbieri MA, Fernandez-Pol S, Hunker C, Horazdovsky BH, Stahl PD. Role of rab5 in EGF receptor-mediated signal transduction. Eur J Cell Biol. 2004;83:305–14.

    Article  PubMed  CAS  Google Scholar 

  14. Chen PI, Kong C, Su X, Stahl PD. Rab5 isoforms differentially regulate the trafficking and degradation of epidermal growth factor receptors. J Biol Chem. 2009;284:30328–38.

    Article  PubMed  CAS  Google Scholar 

  15. Tomshine JC, Severson SR, Wigle DA, Sun Z, Beleford DA, Shridhar V, Horazdovsky BF. Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. J Biol Chem. 2009;284:26331–9.

    Article  PubMed  CAS  Google Scholar 

  16. Senda K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Analysis of RIN1 gene expression in colorectal cancer. Oncol Rep. 2007;17:1171–5.

    PubMed  CAS  Google Scholar 

  17. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J. RIN1 is a breast tumour suppressor gene. Cancer Res. 2007;67:11510–6.

    Article  PubMed  CAS  Google Scholar 

  18. Eble JN, Sauter G, Epstei JI, Sesterhenn IA. (Eds.): World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press; Lyon 2004.

  19. Thomsen R, Solvsten CA, Linnet TE, Blechingberg J, Nielsen AL. Analysis of qPCR data by converting exponentially related Ct values into linearly related X0 values. J Bioinform Comput Biol. 2010;8:885–900.

    Article  PubMed  CAS  Google Scholar 

  20. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17:1395–413.

    Article  PubMed  CAS  Google Scholar 

  21. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998;273:19925–8.

    Article  PubMed  CAS  Google Scholar 

  22. Herrmann C, Horn G, Spaargaren M, Wittinghofer A. Differential interaction of the Ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem. 1996;271:6794–800.

    Article  PubMed  CAS  Google Scholar 

  23. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature. 1994;371:171–5.

    Article  PubMed  CAS  Google Scholar 

  24. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumour suppressor in the lung. J Biol Chem. 2003;278:21938–43.

    Article  PubMed  CAS  Google Scholar 

  25. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Nore1 as a potential Ras effector. J Biol Chem. 1998;273:5439–42.

    Article  PubMed  CAS  Google Scholar 

  26. Feig LA, Urano T, Cantor S. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci. 1996;21:438–41.

    Article  PubMed  CAS  Google Scholar 

  27. Taya S, Yamamoto T, Kano K, Kawano Y, Iwamatsu A, Tsuchiya T, Tanaka K, Kanai-Azuma M, Wood SA, Mattick JS, Kaibuchi K. The Ras target AF-6 is a substrate of the fam deubiquitinating enzyme. J Cell Biol. 1998;142:1053–62.

    Article  PubMed  CAS  Google Scholar 

  28. Kuriyama M, Harada N, Kuroda S, Yamamoto T, Nakafuku M, Iwamatsu A, Yamamoto D, Prasad R, Croce C, Canaani E, Kaibuchi K. Identification of AF-6 and canoe as putative targets for Ras. J Biol Chem. 1996;271:607–10.

    Article  PubMed  CAS  Google Scholar 

  29. Wang Y, Colicelli J. Ras interaction with effector target RIN1. Methods Enzymol. 2001;332:139–51.

    Article  PubMed  CAS  Google Scholar 

  30. Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 1997;6:773–82.

    Article  PubMed  CAS  Google Scholar 

  31. Wang Y, Waldron RT, Dhaka A, Patel A, Riley MM, Rozengurt E, Colicelli J. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol. 2002;22:916–26.

    Article  PubMed  CAS  Google Scholar 

  32. Kajiho H, Sakurai K, Minoda T, Yoshikawa M, Nakagawa S, Fukushima S, Kontani K, Katada T. Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. J Biol Chem. 2011;286:24364–73.

    Article  PubMed  CAS  Google Scholar 

  33. Woller B, Luiskandl S, Popovic M, Prieler BE, Ikonge G, Mutzl M, Rehmann H, Herbst R. Rin-like, a novel regulator of endocytosis, acts as guanine nucleotide exchange factor for Rab5a and Rab22. Biochim Biophys Acta. 2011;1813:1198–210.

    Article  PubMed  CAS  Google Scholar 

  34. Saito K, Kajiho H, Araki Y, Kurosu H, Kontani K, Nishina H, Katada T. Purification and analysis of RIN family-novel Rab5 GEFs. Methods Enzymol. 2005;403:276–83.

    Article  PubMed  CAS  Google Scholar 

  35. Kajiho H, Saito K, Tsujita K, Kontani K, Araki Y, Kurosu H, Katada T. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116:4159–68.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by Doctoral Fund of Ministry of Education of China (20092104120007) and Science and Technology Planning Project of Liaoning Province, China (2010225032).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning Province, 110001, People’s Republic of China

    Guang-yi Shan, Zhe Zhang, Qi-guang Chen, Xiu-yue Yu, Guo-bin Liu & Chui-ze Kong

Authors
  1. Guang-yi Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhe Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi-guang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiu-yue Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo-bin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chui-ze Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chui-ze Kong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shan, Gy., Zhang, Z., Chen, Qg. et al. Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumor Biol. 33, 847–855 (2012). https://doi.org/10.1007/s13277-011-0311-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0311-1

Keywords

Search

Navigation